Opportunity Information: Apply for PAR 19 312
This funding opportunity, PAR-19-312, is a limited-competition renewal announcement from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). It supports Phase 2 renewals of existing Centers of Biomedical Research Excellence (COBRE) awards under the P20 mechanism, with clinical trials listed as optional. In practical terms, it is meant for institutions that already hold an eligible COBRE Phase 1 award and are seeking to continue and deepen the center they built during the initial phase rather than starting a brand-new center from scratch.
The central purpose of the COBRE program is to strengthen an institution's biomedical research infrastructure by building a thematic, multidisciplinary center that can serve as a hub for research capacity. A key emphasis is investigator development: COBRE is designed to help researchers at the institution reach the point where they can successfully compete for independent NIH research awards (for example, R01s) or other high-quality, peer-reviewed external funding. Rather than only funding individual projects, COBRE is structured to create an environment that makes strong research more likely over the long term, such as shared scientific resources, mentoring, and coordinated research activities tied to a coherent scientific theme.
COBRE sits within the broader Institutional Development Award (IDeA) Program. The IDeA program targets institutions in states that have historically had lower overall success rates in obtaining NIH funding, with the intent of improving competitiveness and expanding health-related research capability in those regions. This Phase 2 renewal opportunity continues that mission by supporting centers that have already demonstrated progress in Phase 1 and are ready to further solidify infrastructure and expand the impact of their research community.
For Phase 2 specifically, the goal is to build on what the Phase 1 COBRE established. The announcement describes Phase 2 as a period for further strengthening research infrastructure and continuing the development and support of a critical mass of investigators working within the center's scientific areas. "Critical mass" here reflects the idea that sustainable research excellence depends on more than one or two standout labs; it requires a connected group of investigators with the expertise, resources, and collaborative structure needed to produce competitive science and keep it going beyond the COBRE award period.
Eligibility is restricted. The listed eligible applicant type includes public and state-controlled institutions of higher education, and the opportunity is limited to renewal of eligible COBRE grants (meaning an institution generally must already have an appropriate COBRE Phase 1 award to be considered). Foreign participation is explicitly limited: non-U.S. entities (foreign institutions) are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined in NIH policy) are not allowed. Applicants are expected to consult the full funding announcement for the precise eligibility rules and definitions.
Administrative details provided include that this is a discretionary grant opportunity in the health area, associated with CFDA number 93.859, administered by NIH/NIGMS. The opportunity was created on 2019-07-10, and the original closing date listed is 2021-09-28. The excerpted data does not specify an award ceiling or expected number of awards, indicating applicants would need to review the full announcement for budget limits, project period expectations, and other application requirements.Apply for PAR 19 312
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 - Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.859.
- This funding opportunity was created on 2019-07-10.
- Applicants must submit their applications by 2021-09-28. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): PAR-19-312 (NIGMS/NIH COBRE Phase 2 Renewal)
What is PAR-19-312?
PAR-19-312 is a limited-competition renewal funding opportunity from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). It supports Phase 2 renewals of existing Centers of Biomedical Research Excellence (COBRE) awards under the P20 mechanism.
Is this opportunity for new COBRE centers or renewals?
This opportunity is specifically for Phase 2 renewals of existing COBRE awards. It is intended for institutions that already hold an eligible COBRE Phase 1 award and want to continue and deepen the center established during Phase 1, rather than start a brand-new center.
Which NIH institute administers this program?
The program is administered by NIH through the National Institute of General Medical Sciences (NIGMS).
What grant mechanism does this opportunity use?
The funding opportunity supports COBRE awards under the P20 mechanism.
Are clinical trials allowed under this opportunity?
Clinical trials are listed as optional for this funding opportunity.
What is the central purpose of the COBRE program?
The COBRE program is designed to strengthen an institution's biomedical research infrastructure by building a thematic, multidisciplinary center that serves as a hub for research capacity. It emphasizes creating an environment that supports strong research over the long term, such as shared scientific resources, mentoring, and coordinated research activities aligned to a coherent scientific theme.
What does COBRE emphasize besides research projects?
Rather than only funding individual projects, COBRE is structured to build sustainable institutional capacity. Key elements include investigator development, shared resources, mentoring, and coordinated research efforts tied to a central theme.
What is meant by "investigator development" in COBRE?
Investigator development refers to COBRE's focus on helping researchers at the institution reach a level where they can successfully compete for independent NIH research awards (for example, R01s) or other high-quality, peer-reviewed external funding.
How does COBRE relate to the IDeA Program?
COBRE sits within the broader Institutional Development Award (IDeA) Program. The IDeA Program targets institutions in states that have historically had lower overall success rates in obtaining NIH funding, with the goal of improving competitiveness and expanding health-related research capacity in those regions.
What is the goal of Phase 2 for COBRE?
Phase 2 is intended to build on what was established during Phase 1 by further strengthening research infrastructure and continuing the development and support of a critical mass of investigators working within the center's scientific areas.
What does "critical mass of investigators" mean in this context?
"Critical mass" reflects the idea that sustainable research excellence requires more than a small number of strong labs. It depends on a connected group of investigators with appropriate expertise, resources, and collaborative structures to produce competitive science and maintain momentum beyond the COBRE award period.
Who is eligible to apply?
Eligibility is restricted. The listed eligible applicant type includes public and state-controlled institutions of higher education, and the opportunity is limited to renewal of eligible COBRE grants (generally meaning the institution must already have an appropriate COBRE Phase 1 award to be considered).
Is this a limited competition opportunity?
Yes. It is described as a limited-competition renewal announcement, indicating it is restricted to institutions with eligible existing COBRE Phase 1 awards.
Are foreign institutions eligible to apply?
No. Non-U.S. entities (foreign institutions) are not eligible to apply.
Can a U.S. organization apply if it has a non-U.S. component?
No. Non-U.S. components of U.S. organizations are not eligible under this opportunity.
Are foreign components allowed in any form?
No. Foreign components (as defined in NIH policy) are not allowed.
What field or area does this grant fall under?
It is described as a discretionary grant opportunity in the health area and is administered by NIH/NIGMS.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA number 93.859.
When was this funding opportunity created?
The opportunity was created on 2019-07-10.
What is the listed closing date for this opportunity?
The original closing date listed is 2021-09-28.
Does the provided information include an award ceiling or number of expected awards?
No. The excerpted information does not specify an award ceiling or the expected number of awards.
Where can applicants find budget limits, project period expectations, and application requirements?
The provided information indicates applicants should consult the full funding announcement for details such as budget limits, project period expectations, and other application requirements.
Browse more opportunities from the same category: Health
Next opportunity: FY 2019 Citizenship and Assimilation Grant Program: Citizenship Instruction and Naturalization Application Services
Previous opportunity: Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 19 312
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 19 312) also looked into and applied for these:
| Funding Opportunity |
|---|
| Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 19 315 Funding Number: PAR 19 315 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) Apply for RFA RM 19 011 Funding Number: RFA RM 19 011 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Mechanisms of Tolerance (R21/R33 - Clinical Trial Required) Apply for PAR 19 311 Funding Number: PAR 19 311 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 - Clinical Trial Optional) Apply for PAR 19 313 Funding Number: PAR 19 313 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Specialized Alcohol Research Centers (P50 Clinical trial Optional) Apply for RFA AA 20 001 Funding Number: RFA AA 20 001 Agency: National Institutes of Health Category: Health Funding Amount: $1,150,000 |
| Comprehensive Alcohol Research Centers (P60 Clinical Trial Optional) Apply for RFA AA 20 002 Funding Number: RFA AA 20 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| NIA Program Project Applications (P01 Clinical Trial Optional) Apply for PAR 19 314 Funding Number: PAR 19 314 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Partnerships Initiative (NPI) – Global Health Apply for 7200AA19APS00013 Funding Number: 7200AA19APS00013 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| Connecting Kids to Coverage (CKC) HEALTHY KIDS AI/AN Apply for CMS 2D2 20 001 Funding Number: CMS 2D2 20 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $750,000 |
| Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) Apply for PAS 19 316 Funding Number: PAS 19 316 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) Apply for PAS 19 317 Funding Number: PAS 19 317 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required) Apply for RFA AG 20 011 Funding Number: RFA AG 20 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed) Apply for RFA AG 20 010 Funding Number: RFA AG 20 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Microbiome and Aging: Impact on Health and Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 030 Funding Number: RFA AG 20 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Preclinical Screening for Natural Product Drug Interactions (Clinical Trial Not Allowed, R21) Apply for RFA AT 20 001 Funding Number: RFA AT 20 001 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) Apply for PAR 19 328 Funding Number: PAR 19 328 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 19 329 Funding Number: PAR 19 329 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) Apply for PAR 19 330 Funding Number: PAR 19 330 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Required Apply for PAR 19 335 Funding Number: PAR 19 335 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Biological Mechanisms of Metformin Effects on Aging and Longevity (R01 Clinical Trial Not Allowed) Apply for RFA AG 20 044 Funding Number: RFA AG 20 044 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 19 312", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.